The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Open accessAbstract
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationInterval Estimation for a Binomial Proportion
Brown, L. D., Cai, T., & Dasgupta, A. (2001) · Statistical Science · doi:10.1214/ss/1009213286 · Cited by 3,746
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Cited by
Sorted by citations
Items 501–600 of 1,001
Current advances in immunotherapy for cancer
Desai, I., Thakur, S., & Pagariya, P. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100652 · Cited by 27
Yu, W., Li, P., Zhou, L., Yang, M., Ye, S., Zhu, D., Huang, J., Yao, X., Zhang, Y., Li, L., et al. (2025) · Blood · doi:10.1182/blood.2024026401 · Cited by 27
Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review
Al-Mansour, M. M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.07.017 · Cited by 28
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
Hirayama, A. V. V., Chou, C. K., Miyazaki, T., Steinmetz, R. N., Di, H. A., Fräßle, S. P., Gauthier, J., Fiorenza, S., Hawkins, R. M., Overwijk, W. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008697 · Cited by 25
Current state of CAR-T therapy for T-cell malignancies
Luo, L., Zhou, X., Zhou, L., Liang, Z., Yang, J., Tu, S., & Li, Y. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221143025 · Cited by 28
Powell, M. Z., Mara, K. C., Bansal, R., Hathcock, M. A., Khurana, A., Bennani, N. N., Wang, Y., Paludo, J., Villasboas, J. C., Ansell, S. M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5665 · Cited by 27
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
Bansal, R., Baksh, M., Larsen, J. T., Hathcock, M. A., Dingli, D., Stewart, A. K., Kapoor, P., Kourelis, T., Hayman, S. R., Warsame, R. M., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00820-y · Cited by 27
Jain, N. K., Mamgain, M., Chowdhury, S. M., Jindal, U., Sharma, I., Sehgal, L., & Epperla, N. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01496-4 · Cited by 27
Andrea, A. E., Chiron, A., Sarrabayrouse, G., Bessoles, S., & Hacein‐Bey‐Abina, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1459818 · Cited by 28
Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach
Bu, T., Yang, W., Zhao, J., Gao, Y., Li, F., & Yang, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010379 · Cited by 32
Cytokine release syndrome in solid tumors
Synnott, D., O’Reilly, D., de Freitas, D. G., & Naidoo, J. (2025) · Cancer · doi:10.1002/cncr.70069 · Cited by 27
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
Kang, C. H., Kim, Y., Lee, H. K., Lee, S. M., Jeong, H. G., Choi, S. U., & Park, C. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239163 · Cited by 26
Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 28
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
Zurko, J. C., Fenske, T. S., Johnson, B. D., Bucklan, D., Szabó, A., Xu, H., Chaney, K., Hamadani, M., Hari, P., & Shah, N. N. (2022) · American Journal of Hematology · doi:10.1002/ajh.26718 · Cited by 26
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
Jang, J.-Y., Hwang, I., Pan, H., Yao, J., Alinari, L., Imada, E. L., Zanettini, C., Kluk, M., Wang, Y., Lee, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160767 · Cited by 26
Application of adoptive cell therapy in hepatocellular carcinoma
Wu, D., & Li, Y. (2023) · Immunology · doi:10.1111/imm.13677 · Cited by 29
Zhang, Q., Zhu, X., & Xiao, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05640-z · Cited by 26
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges
Ong, M. Z., Kimberly, S. A., Lee, W.-H., Ling, M., Lee, M., Tan, K.-W., Foo, J. B., Yow, H.-Y., Sellappans, R., & Hamzah, S. B. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010257212231001082741 · Cited by 29
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Negishi, S., Girsch, J. H., Siegler, E. L., Bezerra, E. D., Miyao, K., & Sakemura, R. L. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1305657 · Cited by 27
Yamshon, S., Gribbin, C. K., Alhomoud, M., Chokr, N., Chen, Z., Demetres, M. R., Pasciolla, M. S., Leonard, J. P., Shore, T. B., & Martin, P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.007 · Cited by 25
Korell, F., Entenmann, L., Romann, S. W., Giannitsis, E., Schmitt, A., Müller‐Tidow, C., Frey, N., Dreger, P., Schmitt, M. W., & Lehmann, L. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102504 · Cited by 26
Bindal, P., Patell, R. D., Chiasakul, T., Lauw, M. N., Ko, A., Wang, T., & Zwicker, J. I. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.03.021 · Cited by 26
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
Gatwood, K. S., Mahmoudjafari, Z., Baer, B., Pak, S., Lee, B., Kim, H., Abernathy, K. M., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.115793 · Cited by 25
Yoshikawa, T., Ito, Y., Wu, Z., Kasuya, H., Nakashima, T., Okamoto, S., Amaishi, Y., Zhang, H., Li, Y., Matsukawa, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101526 · Cited by 26
Ohta, K., Sakoda, Y., Adachi, K., Shinozaki, T., Nakajima, M., Yasuda, H., Nagano, H., & Tamada, K. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0226 · Cited by 30
The current socioeconomic and regulatory landscape of immune effector cell therapies
Sainatham, C., Yadav, D., Babu, A. D., Tallapalli, J. R., Kanagala, S. G., Filippov, E., Murillo-Chavez, F., Ahmed, N., & Lutfi, F. U. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462307 · Cited by 30
Yi, E., Lee, E., Park, H. J., Lee, H. H., Yun, S., & Kim, H. S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03351-5 · Cited by 30
Wang, M. L., Jain, P., Chi, T., Chen, S. E., Heimberger, A. B., Weathers, S.-P. S., Zheng, L., Rao, A. V., & Rossi, J. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001114 · Cited by 25
Self-citationComprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer
Yu, J., Zhang, Q., Wang, M., Liang, S., Huang, H., Xie, L., Cui, C., & Yu, J. (2021) · Bioscience Reports · doi:10.1042/bsr20203336 · Cited by 25
Self-citationSimons, C., Malone, D. C., Wang, M. L., Maglinte, G. A., Inocencio, T. J., Wade, S. W., Bennison, C., & Shah, B. D. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1894158 · Cited by 26
Self-citationResistance to CART cell therapy: lessons learned from the treatment of hematological malignancies
Sakemura, R. L., Cox, M. J., Hefazi, M., Siegler, E. L., & Kenderian, S. S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894648 · Cited by 25
Tang, K., & Nastoupil, L. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-2 · Cited by 25
Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy
Chung, H., Jung, H., & Noh, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212126 · Cited by 28
Stock, S., Kluever, A.-K., Endres, S., & Kobold, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020307 · Cited by 25
Dholaria, B., Mehraban, N., Baer, B., Long, N., Jayani, R., Byrne, M. T., Kassim, A. A., Engelhardt, B. G., Savani, B. N., & Oluwole, O. O. (2022) · British Journal of Haematology · doi:10.1111/bjh.18339 · Cited by 25
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
Zhou, J., Zhang, Y., Shan, M., Zong, X., Geng, H., Li, J., Chen, G., Yu, L., Xu, Y., Li, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997589 · Cited by 26
Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers
Feng, Q., Sun, B., Xue, T., Li, R., Lin, C., Gao, Y., Sun, L., Zhuo, Y., & Wang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025608 · Cited by 25
Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA
Warga, E., Anderson, J. L., Tucker, M., Harris, E., & Elmer, J. J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.025 · Cited by 28
Lau, E. K., Kwong, G., Fowler, T. W., Sun, B.-C., Donohoue, P. D., Davis, R. T., Bryan, M. B., McCawley, S., Clarke, S., Williams, C., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.03.011 · Cited by 25
Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
Xie, D., Jin, X. K., Sun, R., Zhang, M., Lu, W., Cao, X., Guo, R., Zhang, Y., & Zhao, M. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101695 · Cited by 25
Villa, D. R., Jiang, A., Visco, C., Crosbie, N., McCulloch, R., Buege, M. J., Kumar, A. A., Bond, D. A., Paludo, J., Maurer, M. J., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009804 · Cited by 25
Calviño, C., Ceballos, C., Piérola, A. A., Jáuregui, P., Calleja-Cervantes, M. E., Martín‐Úriz, P. S., Rodríguez-Márquez, P., Martín-Mallo, Á., Iglesias, E., Abizanda, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270843 · Cited by 26
Pérez-Moreno, M. A., Ciudad-Gutiérrez, P., Jaramillo-Ruiz, D., Reguera, J. L., Martín, L. A., & Flores‐Moreno, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914780 · Cited by 25
Davis, J. E., Handunnetti, S. M., Ludford‐Menting, M., Sharpe, C., Blombery, P. A., Anderson, M. A., Roberts, A. W., Seymour, J. F., Tam, C. S. L., Ritchie, D. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002810 · Cited by 25
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Karschnia, P., Blobner, J., Teske, N., Schöberl, F., Fitzinger, E., Dreyling, M. H., Tonn, J., Thon, N., Subklewe, M. S., & von Baumgarten, L. (2021) · Cancers · doi:10.3390/cancers13102503 · Cited by 25
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 29
Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 27
Ullrich, F., Bröckelmann, P. J., Turki, A. T., Khan, A., Chiru, E.-D., Vetter, M. H. F., von Tresckow, B., Wirth, R., Córdoba, R., Ortiz‐Maldonado, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009462 · Cited by 25
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
Patel, S. A., Spiegel, J. Y., & Dahiya, S. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5412 · Cited by 24
Allogeneic CART progress: platforms, current progress and limitations
Shokati, A., Sanjari-Pour, M., Rahnama, M. A., Hoseinzadeh, S., Vaezi, M., & Ahmadvand, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557157 · Cited by 29
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Xu, Y., Jiang, J., Wang, Y., Wang, W., Li, H., Lai, W., Zhou, Z., Zhu, W., Xiang, Z., Wang, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.725330 · Cited by 27
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
Gea‐Banacloche, J. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.02.003 · Cited by 24
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Mucha, S. R., & Rajendram, P. (2023) · Current Oncology · doi:10.3390/curroncol30050378 · Cited by 26
Jacobson, C. A., Rosenthal, A. C., Arnason, J. E., Agarwal, S., Zhang, P., Wu, W., Amber, V., & Yared, J. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009961 · Cited by 24
Self-citationRossi, M., Steklov, M. Y., Huberty, F., Nguyen, T., Marijsse, J., Jacques-Hespel, C., Najm, P., Lonez, C., & Breman, E. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102038 · Cited by 26
Sakemura, R. L., Roman, C. M., Horvei, P., Siegler, E. L., Girsch, J. H., Sirpilla, O. L., Stewart, C. M., Yun, K., Can, İ., Ogbodo, E. J., et al. (2023) · Blood · doi:10.1182/blood.2022018905 · Cited by 25
Martínez‐Cibrián, N., Ortiz‐Maldonado, V., Español‐Rego, M., Blázquez, A., Cid, J., Lozano, M., Magnano, L., Giné, E., Correa, J. G., Mozas, P., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19170 · Cited by 24
Yu, C., Hsieh, K., Cherry, D. R., Nehlsen, A. D., Salgado, L. R., Lazarev, S., & Sindhu, K. K. (2023) · Biology · doi:10.3390/biology12121528 · Cited by 25
Wang, Y., Cho, J.-W., Kastrunes, G. M., Buck, A., Razimbaud, C., Culhane, A. C., Sun, J., Braun, D. A., Choueiri, T. K., Wu, C. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108879 · Cited by 25
Joy, J. D., Malacrida, B., Laforêts, F., Kotantaki, P., Maniati, E., Manchanda, R., Annibaldi, A., Hopkins, S., Garrobo-Calleja, I., Gautrot, J. E., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3007 · Cited by 22
Boosting CAR-T cell therapy with CRISPR technology
Yan, L., Gao, S., Wang, X., Zhou, X., Limsakul, P., & Wu, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.06.002 · Cited by 24
The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective
Yin, H., & Wei, X. (2025) · MedComm · doi:10.1002/mco2.70067 · Cited by 27
Park, J. H., Palomba, M. L., Perica, K., Devlin, S. M., Shah, G. L., Dahi, P. B., Lin, R. J., Salles, G., Scordo, M., Nath, K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02424 · Cited by 23
Management of Drug Resistance in Mantle Cell Lymphoma
Roué, G., & Sola, B. (2020) · Cancers · doi:10.3390/cancers12061565 · Cited by 27
Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
Goldsmith, S. R., Ghobadi, A., & DiPersio, J. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.608916 · Cited by 25
CRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 25
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
Wutti‐in, Y., Sujjitjoon, J., Sawasdee, N., Panya, A., Kongkla, K., Yuti, P., Yongpitakwattana, P., Thepmalee, C., Junking, M., Chieochansin, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.802876 · Cited by 24
Can, İ., Cox, M. J., Siegler, E. L., Sakemura, R. L., & Kenderian, S. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.02.001 · Cited by 23
Oswald, L. B., Li, X., Carvajal, R., Hoogland, A. I., Gudenkauf, L. M., Hansen, D. K., Alsina, M., Locke, F. L., Rodriguez, Y., Irizarry-Arroyo, N. E., et al. (2022) · Cancers · doi:10.3390/cancers14112742 · Cited by 23
Self-citationKast, J., Nozohouri, S., Zhou, D., Yago, M. R., Chen, P., Ahamadi, M., Dutta, S., & Upreti, V. V. (2022) · Clinical and Translational Science · doi:10.1111/cts.13349 · Cited by 23
Zanubrutinib in lymphoproliferative disorders: a comprehensive review
Munoz, J. L., Wang, Y., Jain, P., & Wang, M. L. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221093980 · Cited by 23
Self-citationDupouy, S., Marchiq, I., Derippe, T., Almena-Carrasco, M., Jóźwik, A., Fouliard, S., Adimy, Y., Geronimi, J., Graham, C., Jain, N., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0175 · Cited by 23
Acute Kidney Injury in Cancer Immunotherapy Recipients
Joseph, A., Lafarge, A., Azoulay, É., & Zafrani, L. (2022) · Cells · doi:10.3390/cells11243991 · Cited by 23
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Bonini, C., Chapuis, A. G., Hudecek, M., Guedan, S., Magnani, C. F., & Qasim, W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.128 · Cited by 29
Kaulen, L. D., Martinez‐Lage, M., Abramson, J. S., Karschnia, P., Doubrovinskaia, S., Shankar, G. M., Choi, B. D., Ramundo, C. M., Ehret, F., Barnes, J. A., et al. (2025) · Blood · doi:10.1182/blood.2025028964 · Cited by 24
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
Bond, D. A., Martin, P., & Maddocks, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061207 · Cited by 24
Karmali, R., Switchenko, J. M., Goyal, S., Shanmugasundaram, K., Churnetski, M. C., Kolla, B. C., Bachanová, V., Gerson, J. N., Barta, S. K., Gordon, M. J., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26306 · Cited by 22
Self-citationMultipurposing CARs: Same engine, different vehicles
Hossian, A. K. M. N., Hackett, C. S., Brentjens, R. J., & Rafiq, S. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.012 · Cited by 24
Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy
Jiang, Y., Wen, W., Yang, F., Han, D., Zhang, W., & Qin, W. (2022) · Cancers · doi:10.3390/cancers14040967 · Cited by 26
Anderson, M. K., Torosyan, A., & Halford, Z. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211026338 · Cited by 22
Lapidus, A. H., Anderson, M. A., Harrison, S. J., Dickinson, M. J., Kalinčík, T., & Lasocki, A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2074990 · Cited by 22
Apoptosis: a Janus bifrons in T-cell immunotherapy
Lee, Y. G., Yang, N., Chun, I., Porazzi, P., Carturan, A., Paruzzo, L., Sauter, C. T., Guruprasad, P., Pajarillo, R., & Ruella, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005967 · Cited by 24
CRISPR, CAR-T, and NK: Current applications and future perspectives
Khoshandam, M., Soltaninejad, H., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101121 · Cited by 25
Chan, W. K., Williams, J. L., Sorathia, K., Pray, B. A., Abusaleh, K., Bian, Z., Sharma, A., Hout, I., Nishat, S., Hanel, W. G., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00437-8 · Cited by 22
Long‐term survivorship care after CAR‐T cell therapy
Puckrin, R., Jamani, K., & Jimenez-Zepeda, V. H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14100 · Cited by 26
Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies
Luo, Y., Qie, Y., Gadd, M. E., Manna, A., Rivera-Valentin, R. K., To, T., Li, S., Yassine, F., Murthy, H. S., Dronca, R. S., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03537-w · Cited by 22
Estimation of eligibility for and response to CAR-T therapy in the United States
Haslam, A., Høeg, T. B., & Prasad, V. K. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011184 · Cited by 22
Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy
Johnson, P. C., Neckermann, I., Sadrzadeh, H., Newcomb, R. A., El-Jawahri, A. R., & Frigault, M. J. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.02.019 · Cited by 22
Melilli, E., Mussetti, A., Sanz‐Linares, G., Ruella, M., Charette, L., Savchenko, A., Taco, M. D. R., Montero, N., Grinyo, J. M., Favà, A., et al. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.03.011 · Cited by 22
Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies
Nguyen, T., Greene, L. A., Mnatsakanyan, H., & Badr, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061376 · Cited by 13
Treatment of relapsed/refractory MCL
Silkenstedt, E., & Dreyling, M. H. (2024) · Blood · doi:10.1182/blood.2023022353 · Cited by 24
Cardiovascular toxicities associated with novel cellular immune therapies
Munir, M., Sayed, A., Addison, D., & Epperla, N. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013849 · Cited by 27
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu, J., Yan, Z., & Hai, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492552 · Cited by 23
Guégan, M., Bichon, M., Chaput, N., Houot, R., & Lemoine, J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115145 · Cited by 23
Self-citationHigh-risk MCL: recognition and treatment
Jain, P., & Wang, M. L. (2024) · Blood · doi:10.1182/blood.2023022354 · Cited by 23
Self-citationA Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies
Parums, D. (2025) · Medical Science Monitor · doi:10.12659/msm.948125 · Cited by 25
Gazeau, N., Beauvais, D., Tilmont, R., Srour, M., Ferrant, E., Safar, V., Fouillet, L., Flandrin-Gresta, P., Gower, N., Chauvet, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02605-7 · Cited by 24
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 28
CAR T cell persistence in cancer
Mueller, K. P., Grenier, J. M., & Weber, E. W. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.014 · Cited by 22
Metadata
- Authors
- Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M.-J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., Peng, W., Zheng, L., Rossi, J. M., Jain, R. K., Rao, A. V., & Reagan, P. M.
- Affiliations
- Cleveland Clinic (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (M.W.), and Texas Oncology, Dallas (H.H.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); John Theurer Cancer Center, Hackensack, NJ (A.G.); Moffitt Cancer Center, Tampa (F.L.L.), and the University of Miami, Miami (A.B.) — both in Florida; Dana–Farber Cancer Institute, Boston (C.A.J.); Cleveland Clinic Foundation, Cleveland (B.T.H.), and the Ohio State University Comprehensive Cancer Center, Columbus (S.J.); David Geffen...
- Fox Chase Cancer Center (US)
- Corresponding author
- Wang, Michael
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-02
- Volume
- 382
- Issue
- 14
- Pages
- 1331-1342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7731441
- OpenAlex
- W3014583893
- Cited by
- 1,862
- References
- 30
- Citations by year
- 2026: 203 · 2025: 249 · 2024: 314 · 2023: 321 · 2022: 366 · 2021: 321 · 2020: 81
- FWCI
- 98.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Funders
- Kite, a Gilead Company
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CD19 CAR T-cell therapy, BTK inhibitor resistance, objective response, complete response, progression-free survival, overall survival, cytokine release syndrome, neurological adverse events, cytopenia
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Humans, Infusions, Intravenous, Leukapheresis, Middle Aged, Recurrence, T-Lymphocytes, Vidarabine, Survival Analysis, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Mantle-Cell
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
